108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
关于 EGFR 外显子 20 插入突变且 PD-L1 高表达的晚期肺腺癌患者使用 Sunvozertinib 单药治疗的病例报告
Received 26 February 2025
Accepted for publication 31 August 2025
Published 18 September 2025 Volume 2025:17 Pages 2069—2076
DOI https://doi.org/10.2147/CMAR.S524920
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Professor Lu-Zhe Sun
Juan Zhou, Hui Han
Department of Oncology, Liaocheng People’s Hospital, Liaocheng City, Shandong Province, 252000, People’s Republic of China
Correspondence: Hui Han, Department of Oncology, Liaocheng People’s Hospital, No. 67, Dongchang West Road, Liaocheng City, Shandong Province, 252000, People’s Republic of China, Tel +86-13793058812, Email hh22tt@163.com
Abstract: As a key oncogenic driver in non–small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for 2– 5% of EGFR‐mutated NSCLC cases and display marked heterogeneity. Conventional EGFR tyrosine kinase inhibitors (TKIs) are ineffective against these mutations. Sunvozertinib, an orally administered, potent, and highly selective EGFR-TKI, has been approved in China for second-line treatment of NSCLC harboring EGFR exon 20 insertion mutations. Historically, patients with EGFR exon 20 insertion and high programmed death-ligand 1 (PD-L1) expression often received combined immunotherapy and chemotherapy. In the present case report, we describe a patient who exhibited intolerance to first-line immunochemotherapy and was subsequently switched to sunvozertinib for maintenance therapy. This regimen yielded a prolonged progression-free survival, with manageable safety and tolerability profiles. These findings demonstrated that sunvozertinib could be a promising first-line treatment option for NSCLC patients with EGFR exon 20 insertion.
Keywords: EGFR exon 20 insertion, NSCLC, sunvozertinib, PD-L1
Department of Oncology, Liaocheng People’s Hospital, Liaocheng City, Shandong Province, 252000, People’s Republic of China
Correspondence: Hui Han, Department of Oncology, Liaocheng People’s Hospital, No. 67, Dongchang West Road, Liaocheng City, Shandong Province, 252000, People’s Republic of China, Tel +86-13793058812, Email hh22tt@163.com
Abstract: As a key oncogenic driver in non–small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for 2– 5% of EGFR‐mutated NSCLC cases and display marked heterogeneity. Conventional EGFR tyrosine kinase inhibitors (TKIs) are ineffective against these mutations. Sunvozertinib, an orally administered, potent, and highly selective EGFR-TKI, has been approved in China for second-line treatment of NSCLC harboring EGFR exon 20 insertion mutations. Historically, patients with EGFR exon 20 insertion and high programmed death-ligand 1 (PD-L1) expression often received combined immunotherapy and chemotherapy. In the present case report, we describe a patient who exhibited intolerance to first-line immunochemotherapy and was subsequently switched to sunvozertinib for maintenance therapy. This regimen yielded a prolonged progression-free survival, with manageable safety and tolerability profiles. These findings demonstrated that sunvozertinib could be a promising first-line treatment option for NSCLC patients with EGFR exon 20 insertion.
Keywords: EGFR exon 20 insertion, NSCLC, sunvozertinib, PD-L1